A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations

Sarina A. Piha-Paul, Analía Azaro, Hendrik Tobias Arkenau, Do Youn Oh, Matthew D. Galsky, Sumanta Kumar Pal, Kensuke Hamada, Yaohua He, Ikuo Yamamiya, Karim A. Benhadji, Antoine Hollebecque

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations'. Together they form a unique fingerprint.

Medicine & Life Sciences